Cargando…

Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma

Sphingomyelin is a cell membrane sphingolipid that is upregulated in synovial sarcoma (SS). Jaspine B has been shown to inhibit sphingomyelin synthase, which synthesizes sphingomyelin from ceramide, a critical signal transducer; however, jaspine B’s low bioavailability limits its application as a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khajeh pour, Sana, Mateen, Sameena, Pashikanti, Srinath, Barrott, Jared J., Aghazadeh-Habashi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410108/
https://www.ncbi.nlm.nih.gov/pubmed/36005512
http://dx.doi.org/10.3390/md20080509
_version_ 1784775014284787712
author Khajeh pour, Sana
Mateen, Sameena
Pashikanti, Srinath
Barrott, Jared J.
Aghazadeh-Habashi, Ali
author_facet Khajeh pour, Sana
Mateen, Sameena
Pashikanti, Srinath
Barrott, Jared J.
Aghazadeh-Habashi, Ali
author_sort Khajeh pour, Sana
collection PubMed
description Sphingomyelin is a cell membrane sphingolipid that is upregulated in synovial sarcoma (SS). Jaspine B has been shown to inhibit sphingomyelin synthase, which synthesizes sphingomyelin from ceramide, a critical signal transducer; however, jaspine B’s low bioavailability limits its application as a promising treatment option. To address this shortcoming, we used microfluidics to develop a liposomal delivery system with increased anticancer efficacy. The nano-liposome size was determined by transmission electron microscopy. The jaspine B liposome was tested for its tumor inhibitory efficacy compared to plain jaspine B in in vitro and in vivo studies. The human SS cell line was tested for cell viability using varying jaspine B concentrations. In a mouse model of SS, tumor growth suppression was evaluated during four weeks of treatment (3 times/week). The results show that jaspine B was successfully formulated in the liposomes with a size ranging from 127.5 ± 61.2 nm. The MTT assay and animal study results indicate that jaspine B liposomes dose-dependently lowers cell viability in the SS cell line and effectively suppresses tumor cell growth in the SS animal model. The novel liposome drug delivery system addresses jaspine B’s low bioavailability issues and improves its therapeutic efficacy.
format Online
Article
Text
id pubmed-9410108
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94101082022-08-26 Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma Khajeh pour, Sana Mateen, Sameena Pashikanti, Srinath Barrott, Jared J. Aghazadeh-Habashi, Ali Mar Drugs Article Sphingomyelin is a cell membrane sphingolipid that is upregulated in synovial sarcoma (SS). Jaspine B has been shown to inhibit sphingomyelin synthase, which synthesizes sphingomyelin from ceramide, a critical signal transducer; however, jaspine B’s low bioavailability limits its application as a promising treatment option. To address this shortcoming, we used microfluidics to develop a liposomal delivery system with increased anticancer efficacy. The nano-liposome size was determined by transmission electron microscopy. The jaspine B liposome was tested for its tumor inhibitory efficacy compared to plain jaspine B in in vitro and in vivo studies. The human SS cell line was tested for cell viability using varying jaspine B concentrations. In a mouse model of SS, tumor growth suppression was evaluated during four weeks of treatment (3 times/week). The results show that jaspine B was successfully formulated in the liposomes with a size ranging from 127.5 ± 61.2 nm. The MTT assay and animal study results indicate that jaspine B liposomes dose-dependently lowers cell viability in the SS cell line and effectively suppresses tumor cell growth in the SS animal model. The novel liposome drug delivery system addresses jaspine B’s low bioavailability issues and improves its therapeutic efficacy. MDPI 2022-08-10 /pmc/articles/PMC9410108/ /pubmed/36005512 http://dx.doi.org/10.3390/md20080509 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Khajeh pour, Sana
Mateen, Sameena
Pashikanti, Srinath
Barrott, Jared J.
Aghazadeh-Habashi, Ali
Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma
title Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma
title_full Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma
title_fullStr Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma
title_full_unstemmed Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma
title_short Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma
title_sort formulation, characterization, and in vitro/in vivo efficacy studies of a novel liposomal drug delivery system of amphiphilic jaspine b for treatment of synovial sarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410108/
https://www.ncbi.nlm.nih.gov/pubmed/36005512
http://dx.doi.org/10.3390/md20080509
work_keys_str_mv AT khajehpoursana formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma
AT mateensameena formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma
AT pashikantisrinath formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma
AT barrottjaredj formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma
AT aghazadehhabashiali formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma